Elizabeth Hill

Poster(s):

• (PA-341) Primary Results from A Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
  Wednesday, September 17, 2025